|
1
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eso Y and Marusawa H: Novel approaches for
molecular targeted therapy against hepatocellular carcinoma.
Hepatol Res. 48:597–607. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM,
Kamel IR, Ghasebeh MA and Pawlik TM: Hepatocellular carcinoma: From
diagnosis to treatment. Surg Oncol. 25:74–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshida H, Taniai N, Yoshioka M, Hirakata
A, Kawano Y, Shimizu T, Ueda J, Takata H, Nakamura Y and Mamada Y:
Current status of laparoscopic hepatectomy. J Nippon Med Sch.
86:201–206. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swamy SG, Kameshwar VH, Shubha PB, Looi
CY, Shanmugam MK, Arfuso F, Dharmarajan A, Sethi G, Shivananju NS
and Bishayee A: Targeting multiple oncogenic pathways for the
treatment of hepatocellular carcinoma. Target Oncol. 12:1–10. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Conciatori F, Ciuffreda L, Bazzichetto C,
Falcone I, Pilotto S, Bria E, Cognetti F and Milella M: mTOR
Cross-talk in cancer and potential for combination therapy. Cancers
(Basel). 10:232018. View Article : Google Scholar
|
|
8
|
Fasolo A and Sessa C: Targeting mTOR
pathways in human malignancies. Curr Pharm Des. 18:2766–2777. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matter MS, Decaens T, Andersen JB and
Thorgeirsson SS: Targeting the mTOR pathway in hepatocellular
carcinoma: Current state and future trends. J Hepatol. 60:855–865.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian T, Li X and Zhang J: mTOR Signaling
in cancer and mTOR inhibitors in solid tumor targeting therapy. Int
J Mol Sci. 20:7552019. View Article : Google Scholar
|
|
11
|
Villanueva A, Chiang DY, Newell P, Peix J,
Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, et al:
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology. 135:1972–1983, 1983.e1-11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buitrago-Molina LE, Pothiraju D, Lamlé J,
Marhenke S, Kossatz U, Breuhahn K, Manns MP, Malek N and Vogel A:
Rapamycin delays tumor development in murine livers by inhibiting
proliferation of hepatocytes with DNA damage. Hepatology.
50:500–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Engl T, Rutz J, Maxeiner S, Juengel E,
Roos F, Khoder W, Bechstein WO, Nelson K, Tsaur I, Haferkamp A, et
al: mTOR inhibition reduces growth and adhesion of hepatocellular
carcinoma cells in vitro. Mol Med Rep. 16:7064–7071. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sahin F, Kannangai R, Adegbola O, Wang J,
Su G and Torbenson M: mTOR and P70 S6 kinase expression in primary
liver neoplasms. Clin Cancer Res. 10:8421–8425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Semela D, Piguet AC, Kolev M, Schmitter K,
Hlushchuk R, Djonov V, Stoupis C and Dufour JF: Vascular remodeling
and antitumoral effects of mTOR inhibition in a rat model of
hepatocellular carcinoma. J Hepatol. 46:840–848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomas HE, Mercer CA, Carnevalli LS, Park
J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow
BJ, et al: mTOR inhibitors synergize on regression, reversal of
gene expression, and autophagy in hepatocellular carcinoma. Sci
Transl Med. 4:139ra842012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu AX, Kudo M, Assenat E, Cattan S, Kang
YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, et al: Effect of
everolimus on survival in advanced hepatocellular carcinoma after
failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA.
312:57–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huynh H, Hao HX, Chan SL, Chen D, Ong R,
Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, et al: Loss of
tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular
carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol
Cancer Ther. 14:1224–1235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turano C, Gaucci E, Grillo C and
Chichiarelli S: ERp57/GRP58: A protein with multiple functions.
Cell Mol Biol Lett. 16:539–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hettinghouse A, Liu R and Liu CJ:
Multifunctional molecule ERp57: From cancer to neurodegenerative
diseases. Pharmacol Ther. 181:34–48. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takata H, Kudo M, Yamamoto T, Ueda J,
Ishino K, Peng WX, Wada R, Taniai N, Yoshida H, Uchida E, et al:
Increased expression of PDIA3 and its association with cancer cell
proliferation and poor prognosis in hepatocellular carcinoma. Oncol
Lett. 12:4896–4904. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kondo R, Ishino K, Wada R, Takata H, Peng
WX, Kudo M, Kure S, Kaneya Y, Taniai N, Yoshida H, et al:
Downregulation of protein disulfide isomerase A3 expression
inhibits cell proliferation and induces apoptosis through STAT3
signaling in hepatocellular carcinoma. Int J Oncol. 54:1409–1421.
2019.PubMed/NCBI
|
|
23
|
Ramírez-Rangel I, Bracho-Valdés I,
Vázquez-Macías A, Carretero-Ortega J, Reyes-Cruz G and
Vázquez-Prado J: Regulation of mTORC1 complex assembly and
signaling by GRp58/ERp57. Mol Cell Biol. 31:1657–1671. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hoffstrom BG, Kaplan A, Letso R, Schmid
RS, Turmel GJ, Lo DC and Stockwell BR: Inhibitors of protein
disulfide isomerase suppress apoptosis induced by misfolded
proteins. Nat Chem Biol. 6:900–906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang ZF and Poon RT: Vascular changes in
hepatocellular carcinoma. Anat Rec (Hoboken). 291:721–734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirohashi S, Shimosato Y, Kameya T, Koide
T, Mukojima T, Taguchi Y and Kageyama K: Production of
alpha-fetoprotein and normal serum proteins by xenotransplanted
human hepatomas in relation to their growth and morphology. Cancer
Res. 39:1819–1828. 1979.PubMed/NCBI
|
|
27
|
Doi I: Establishment of a cell line and
its clonal sublines from a patient with hepatoblastoma. Gan.
67:1–10. 1976.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huynh H, Chow KH, Soo KC, Toh HC, Choo SP,
Foo KF, Poon D, Ngo VC and Tran E: RAD001 (everolimus) inhibits
tumour growth in xenograft models of human hepatocellular
carcinoma. J Cell Mol Med. 13:1371–1380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carracedo A, Ma L, Teruya-Feldstein J,
Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma
SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 118:3065–3074. 2008.PubMed/NCBI
|
|
31
|
Newell P, Toffanin S, Villanueva A, Chiang
DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH,
Melgar-Lesmes P, et al: Ras pathway activation in hepatocellular
carcinoma and anti-tumoral effect of combined sorafenib and
rapamycin in vivo. J Hepatol. 51:725–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Piguet AC, Saar B, Hlushchuk R, St-Pierre
MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V
and Dufour JF: Everolimus augments the effects of sorafenib in a
syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer
Ther. 10:1007–1017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang
XW and Tang ZY: Effect of rapamycin alone and in combination with
sorafenib in an orthotopic model of human hepatocellular carcinoma.
Clin Cancer Res. 14:5124–5130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ferrin G, Guerrero M, Amado V,
Rodriguez-Peralvarez M and De la Mata M: Activation of mTOR
signaling pathway in hepatocellular carcinoma. Int J Mol Sci.
21:12662020. View Article : Google Scholar
|
|
35
|
Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble
JR and McCaughan GW: Targeting the vasculature in hepatocellular
carcinoma treatment: Starving versus normalizing blood supply. Clin
Transl Gastroenterol. 8:e982017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morse MA, Sun W, Kim R, He AR, Abada PB,
Mynderse M and Finn RS: The role of angiogenesis in hepatocellular
carcinoma. Clin Cancer Res. 25:912–920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meng D, Frank AR and Jewell JL: mTOR
signaling in stem and progenitor cells. Development.
145:dev1525952018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choe MH, Min JW, Jeon HB, Cho DH, Oh JS,
Lee HG, Hwang SG, An S, Han YH and Kim JS: ERp57 modulates STAT3
activity in radioresistant laryngeal cancer cells and serves as a
prognostic marker for laryngeal cancer. Oncotarget. 6:2654–2666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chung H, Cho H, Perry C, Song J, Ylaya K,
Lee H and Kim JH: Downregulation of ERp57 expression is associated
with poor prognosis in early-stage cervical cancer. Biomarkers.
18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shimoda T, Wada R, Kure S, Ishino K, Kudo
M, Ohashi R, Fujita I, Uchida E, Yoshida H and Naito Z: Expression
of protein disulfide isomerase A3 and its clinicopathological
association in gastric cancer. Oncol Rep. 41:2265–2272.
2019.PubMed/NCBI
|
|
41
|
Zou H, Wen C, Peng Z, Shao YΥ, Hu L, Li S,
Li C and Zhou HH: P4HB and PDIA3 are associated with tumor
progression and therapeutic outcome of diffuse gliomas. Oncol Rep.
39:501–510. 2018.PubMed/NCBI
|
|
42
|
Hussmann M, Janke K, Kranz P, Neumann F,
Mersch E, Baumann M, Goepelt K, Brockmeier U and Metzen E:
Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits
proliferation and increases sensitivity to ionizing radiation and
chemotherapeutics. Oncotarget. 6:39247–39261. 2015. View Article : Google Scholar : PubMed/NCBI
|
